Your browser doesn't support javascript.
loading
Deorphanization strategies for dark chemical matter.
Wassermann, Anne Mai; Tudor, Matthew; Glick, Meir.
Afiliação
  • Wassermann AM; Chemistry Capabilities and Screening, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA. Electronic address: anne.wassermann@merck.com.
  • Tudor M; Chemistry Capabilities and Screening, Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA.
  • Glick M; Chemistry Capabilities and Screening, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA.
Drug Discov Today Technol ; 23: 69-74, 2017 Mar.
Article em En | MEDLINE | ID: mdl-28647088
ABSTRACT
The term dark chemical matter (DCM) was recently introduced for those molecules in a screening collection that have never shown any substantial biological activity despite having been tested in hundreds of high-throughput assays. It was suggested that, if hits emerge from this compound pool in future screening campaigns, they should be prioritized due to their exquisite selectivity profile. In this article we define DCM at our company and describe on-going efforts to shed light on the bioactivity of these apparently silent compounds, with an emphasis on multi-parametric profiling methods. It is also demonstrated that compounds that are dark within one institution might be found active in another, but typically show the foretold selectivity.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Descoberta de Drogas Idioma: En Revista: Drug Discov Today Technol Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Descoberta de Drogas Idioma: En Revista: Drug Discov Today Technol Ano de publicação: 2017 Tipo de documento: Article